ClearPoint Neuro, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC, reporting total revenue of $12.075 million for the third quarter and disclosing key balance sheet and operational figures.

Key Highlights

  • Total Q3 2026 revenue: $12.075 million, up from $8.861 million in Q3 2025, according to the filing.
  • Product revenue: $7.891 million for the three months ended September 30, 2026, compared to $5.361 million in the prior-year period.
  • Service and other revenue: $4.184 million for Q3 2026, versus $3.500 million for Q3 2025.
  • Gross profit: $7.059 million for Q3 2026, compared to $5.600 million for Q3 2025.
  • Accumulated deficit: $245.259 million as of September 30, 2026, up from $216.910 million at December 31, 2025.
  • Cash and cash equivalents: $46.184 million as of September 30, 2026, compared to $45.923 million at December 31, 2025.
  • Shares outstanding: 32,054,268 shares of common stock as of October 21, 2026, per the filing.

ClearPoint Neuro's Third Quarter 2026 Financial Results and Balance Sheet Position

According to the filing, ClearPoint Neuro, Inc. (NASDAQ:CLPT) reported total revenue of $12.075 million for the three months ended September 30, 2026, an increase from $8.861 million for the same period in 2025. For the nine months ended September 30, 2026, total revenue was $35.083 million, compared to $26.561 million for the nine months ended September 30, 2025. The company attributed revenue to two categories: product revenue and service and other revenue.

The filing disclosed cost of revenue of $5.016 million for Q3 2026, resulting in a gross profit of $7.059 million. Research and development costs for the quarter were reported at $4.018 million, compared to $3.452 million in Q3 2025. For the nine months ended September 30, 2026, R&D costs totaled $13.172 million, versus $10.660 million for the comparable period in 2025.

On the balance sheet, the company reported total assets of $112.728 million as of September 30, 2026, up from $97.747 million at December 31, 2025. The increase in total assets was accompanied by a rise in total liabilities to $85.461 million from $69.727 million at year-end 2025, which the filing shows was driven in part by growth in operating lease liabilities, net of current portion, to $22.661 million from $8.461 million. Long-term notes payable, net, stood at $50.840 million. Total stockholders' equity was $27.267 million as of September 30, 2026, compared to $28.020 million at December 31, 2025. Common shares issued and outstanding were 32,051,494 at September 30, 2026, versus 29,368,760 at December 31, 2025.

What Was Disclosed

ClearPoint Neuro filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 revenue of $12.075 million, a gross profit of $7.059 million, total assets of $112.728 million, and an accumulated deficit of $245.259 million.